동향
동향 내용
Dissolution Testing and Specification Criteria for Immediate-Release Solid Oral Dosage Forms
분류 Pharmaceuticals, Guidance 조회 1326
발행년도 2015 등록일 2015-10-02
출처 FDA (바로가기)
This guidance is developed to provide manufacturers with recommendations for submission of new drug applications (NDAs), investigational new drug applications (INDs), and/or abbreviated new drug applications (ANDAs), as appropriate, for immediate-release (IR) tablets and capsules that contain highly soluble drug substances.
 
(후략)

목록



[추천 메일 발송]
추천 메일 발송
받는 분 이메일 @
추천인
리스트 이전글과 다음글
이전글이전글 ERRATUM: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor raionuclide therapy(PRRNT) in neuroendocrine tumours
다음글다음글 SNMMI/ASNC/SCCT Guideline for Cardiac SPECT/CT and PET/CT 1.0